









Markets
/
Stocks
/
nasdaq-kod
/

Kodiak Sciences Inc

KOD

18.652USD

+0.092+0.50%

Market hours （ET）Quotes delayed by 15 min

985.25MMarket Cap

LossP/E TTM



Kodiak Sciences Inc

18.652

+0.092+0.50%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kodiak Sciences Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kodiak Sciences Inc's Score

Industry at a Glance

Industry Ranking

228 / 501

Overall Ranking

404 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Hold

Current Rating

12.400

Target Price

-31.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kodiak Sciences Inc Highlights

StrengthsRisks

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Undervalued

The company’s latest PE is -4.97, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 41.90M shares, decreasing 17.74% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 764.14K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.17.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Kodiak Sciences Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 5.76, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -4.97, which is -88.55% below the recent high of -0.57 and -0.90% above the recent low of -5.01.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 228/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 6.67, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Kodiak Sciences Inc is 14.00, with a high of 24.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Hold

Current Rating

12.400

Target Price

-31.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Kodiak Sciences Inc

KOD

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.58, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 22.33 and the support level at 13.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.51

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Buy

RSI(14)

58.164

Neutral

STOCH(KDJ)(9,3,3)

55.514

Sell

ATR(14)

2.030

Low Volatility

CCI(14)

19.039

Neutral

Williams %R

30.598

Buy

TRIX(12,20)

1.769

Sell

StochRSI(14)

9.635

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

19.182

Sell

MA10

18.759

Sell

MA20

16.369

Buy

MA50

13.459

Buy

MA100

9.819

Buy

MA200

6.987

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 79.33%, representing a quarter-over-quarter decrease of 9.08%. The largest institutional shareholder is The Vanguard, holding a total of 1.82M shares, representing 3.45% of shares outstanding, with 7.92% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

17.31M

Perlroth (Victor D)

2.70M

+24.31%

BlackRock Institutional Trust Company, N.A.

2.69M

-5.25%

Adage Capital Management, L.P.

2.06M

+55.06%

Acadian Asset Management LLC

1.97M

+1.22%

The Vanguard Group, Inc.

Star Investors

1.82M

+7.90%

ICONIQ Capital, LLC

1.27M

TCG Crossover Management, LLC

1.15M

State Street Investment Management (US)

837.22K

-1.42%

Geode Capital Management, L.L.C.

789.68K

-0.49%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 2.88. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.